文献速递临床试验与 GCP流行病学与生物统计

梗死相关心源性休克中的临时机械循环支持:随机试验个体患者数据荟萃分析及6个月随访

Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
PubMed 文献 · Lancet · 2024-09-02

该个体患者数据荟萃分析纳入9项随机对照试验报告(n=1114例),比较早期常规活性机械循环支持(MCS)与对照治疗对急性心肌梗死相关心源性休克(AMICS)患者6个月全因死亡率的影响。结果显示,MCS总体未显著降低6个月死亡率(HR 0.87,95%CI 0.74-1.03;p=0.10),但增加大出血和血管并发症;ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用MCS死亡率降低(HR 0.77,95%CI 0.61-0.97;p=0.024)。

要点

  • 早期常规MCS未显著降低AMICS患者6个月全因死亡率(HR 0.87,95%CI 0.74-1.03;p=0.10)。
  • ST段抬高型心源性休克且无缺氧性脑损伤风险者使用MCS死亡率降低(HR 0.77,95%CI 0.61-0.97;p=0.024)。
  • MCS使用较对照增加大出血(OR 2.64,95%CI 1.91-3.65)和血管并发症(OR 4.43,95%CI 2.37-8.26)。

核心结论

  • 在AMICS患者中使用活性MCS设备未降低6个月死亡率(无论使用何种设备),且增加大出血和血管并发症。
  • ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用MCS后死亡率降低。
  • 因此,MCS的使用应仅限于特定患者。

研究设计与样本

  • 本研究为个体患者数据荟萃分析,检索MEDLINE via PubMed、Cochrane Central Register of Controlled Trials、Embase及ClinicalTrials.gov至2024年1月26日,无语言限制。
  • 纳入比较早期常规活性MCS(随机化后直接在导管室启用)与对照治疗的随机试验,要求有6个月死亡率数据。
  • 共评估9项随机对照试验报告(n=1114例患者),其中4项(n=611例)比较VA-ECMO与对照,5项(n=503例)比较左心室卸载装置与对照;2项试验包含非AMICS患者共55例(44例接受VA-ECMO,11例接受左心室卸载装置)被排除。
  • 患者中位年龄65岁(IQR 57-73);有数据患者1058例中男性845例(79.9%),女性213例(20.1%)。
  • 主要结局采用Cox回归模型计算风险比(HR);本研究在PROSPERO注册,CRD42024504295。

主要发现

  • 早期非选择性MCS使用对6个月死亡率无显著获益(HR 0.87,95%CI 0.74-1.03;p=0.10)。
  • 左心室卸载装置与对照相比无显著差异(HR 0.80,95%CI 0.62-1.02;p=0.075)。
  • 加载装置对死亡率亦无影响(HR 0.93,95%CI 0.75-1.17;p=0.55)。
  • ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用MCS死亡率降低(HR 0.77,95%CI 0.61-0.97;p=0.024)。
  • MCS使用较对照更常见大出血(OR 2.64,95%CI 1.91-3.65)和血管并发症(OR 4.43,95%CI 2.37-8.26)。

关键数值与推荐

  • 主要结局为6个月全因死亡率,比较早期常规活性经皮MCS与对照治疗。
  • MCS总体与对照比较:HR 0.87(95%CI 0.74-1.03;p=0.10)。
  • 左心室卸载装置与对照比较:HR 0.80(95%CI 0.62-1.02;p=0.075)。
  • 加载装置与对照比较:HR 0.93(95%CI 0.75-1.17;p=0.55)。
  • ST段抬高型心源性休克且无缺氧性脑损伤风险患者使用MCS:HR 0.77(95%CI 0.61-0.97;p=0.024)。

临床怎么用

  • 作者认为,MCS的使用应仅限于特定患者。
  • 作者指出,ST段抬高型心源性休克且无缺氧性脑损伤风险的患者使用MCS后死亡率降低。
  • 原文未报告具体的患者选择标准或临床实施流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous active mechanical circulatory support (MCS) devices are being increasingly used in the treatment of acute myocardial infarction-related cardiogenic shock (AMICS) despite conflicting evidence regarding their effect on mortality. We aimed to ascertain the effect of early routine active percutaneous MCS versus control treatment on 6-month all-cause mortality in patients with AMICS. METHODS: In this individual patient data meta-analysis, randomised controlled trials of potential interest were identified, without language restriction, by querying the electronic databases MEDLINE via PubMed, Cochrane Central Register of Controlled Trials, and Embase, as well as ClinicalTrials.gov, up to Jan 26, 2024. All randomised trials with 6-month mortality data comparing early routine active MCS (directly in the catheterisation laboratory after randomisation) versus control in patients with AMICS were included. The primary outcome was 6-month all-cause mortality in patients with AMICS treated with early routine active percutaneous MCS versus control, with a focus on device type (loading, such as venoarterial extracorporeal membrane oxygenation [VA-ECMO] vs unloading) and patient selection. Hazard ratios (HRs) of the primary outcome measure were calculated using Cox regression models. This study is registered with PROSPERO, CRD42024504295. FINDINGS: Nine reports of randomised controlled trials (n=1114 patients) were evaluated in detail. Overall, four randomised controlled trials (n=611 patients) compared VA-ECMO with a control treatment and five randomised controlled trials (n=503 patients) compared left ventricular unloading devices with a control treatment. Two randomised controlled trials also included patients who did not have AMICS, who were excluded (55 patients [44 who were treated with VA-ECMO and 11 who were treated with a left ventricular unloading device]). The median patient age was 65 years (IQR 57-73); 845 (79·9%) of 1058 patients with data were male and 213 (20·1%) were female. No significant benefit of early unselected MCS use on 6-month mortality was noted (HR 0·87 [95% CI 0·74-1·03]; p=0·10). No significant differences were observed for left ventricular unloading devices versus control (0·80 [0·62-1·02]; p=0·075), and loading devices also had no effect on mortality (0·93 [0·75-1·17]; p=0·55). Patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality with MCS use (0·77 [0·61-0·97]; p=0·024). Major bleeding (odds ratio 2·64 [95% CI 1·91-3·65]) and vascular complications (4·43 [2·37-8·26]) were more frequent with MCS use than with control. INTERPRETATION: The use of active MCS devices in patients with AMICS did not reduce 6-month mortality (regardless of the device used) and increased major bleeding and vascular complications. However, patients with ST-elevation cardiogenic shock without risk of hypoxic brain injury had a reduction in mortality after MCS use. Therefore, the use of MCS should be restricted to certain patients only. FUNDING: The Heart Center Leipzig at Leipzig University and the Foundation Institut für Herzinfarktforschung.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Thiele H, Møller JE, Henriques JPS, et al. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up. Lancet. 2024. PMID: 39236726. doi:10.1016/S0140-6736(24)01448-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。